Recipients of CJD-tainted blood and plasma derivatives should not be notified, AABB urges FDA cmte.
RECIPIENTS SHOULD NOT BE NOTIFIED OF CJD-TAINTED BLOOD/PLASMA-DERIVATIVES, AABB urged in an open public hearing statement before FDA's Ad Hoc Advisory Committee on Creutzfeldt-Jakob Disease in Bethesda, Md. June 22. American Association of Blood Banks Transfusion Transmitted Disease Committee spokesperson Steven Kleinman, MD, said: "It would be exceptionally difficult to communicate this remote risk of infection and the symptoms of CJD along with the complete lack of intervention therapy without causing alarm in recipients."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth